贝那普利联用厄贝沙坦治疗射血分数正常心力衰竭的临床观察

Benazepril combined with irbesartan for patients with heart failure and normal ejection fraction

目的探讨贝那普利联用厄贝沙坦治疗射血分数正常心力衰竭（HFNEF）患者的安全性和有效性。方法选取2014年2月至2015年11月本院确诊的HFNEF患者200例，随机分配至两组，治疗组（n=102例）给予贝那普利联用厄贝沙坦治疗，对照组（n=98例）给予贝那普利治疗。两组均进行为期6个月的治疗，比较两组患者6min步行试验（6MWT）、心脏舒张功能超声多普勒指标[E／A比值、E／E＇比值、左室侧壁E峰减速时间（DT）]以及N末端前脑钠肽（NT-proBNP）和血生化的变化。结果联用治疗与贝那普利单用相比，6MWT距离增加，E／A、E／E＇、DT改善，NT-proBNP降低更显著俨〈0．05）。两组治疗方案间对血钾、肌酐的影响差异无统计学意义（P〉0．05）。结论贝那普利联用厄贝沙坦治疗HFNEF患者可产生更有益的疗效，且安全、耐受良好。

Objective To explore the safety and efficacyof benazepril combined with irbesartan for patients with heart failure and normal ejection fraction（HFNEF）. Methods 200 patients diagnosed with HFNEF at our hospital from February, 2014 to November, 2015 were selected and randomly divided into a treatment group （n=I02） and a control group （n=98）. The treatment group were treated with benazepril and irbesartan and the control group benazepdl for 6 months, The six-minute walk test（dMWT）, diastolic function indexes evaluated by ultrasonic cardiogram （E/A, E/E＇ and DT）, as well as the plasma level of NT-proBNP and blood biochemical indicators were compared between these two groups. Results The 6MWT was longer, E/A, E/E＇, and DT were better, and the level of NT-proBNP were lower in the treatment group than in the control group （P 〈 0.05）. There were no statistical differences in the serum levels of potassium and creatinine between these two groups （P〉0.05）. Conclusions Bcnazepfil combined with irbesartan for patients with HFNEF is effective and safe.